Qiming Star | Immune-Mediated Disease Leader Attovia Therapeutics Debuts on Nasdaq | Bilingual
Focused on developing next-generation biotherapeutics for immune-mediated diseases with significant unmet clinical needs.
Swipe Left for the English Version
On August 5, 2026 Beijing time, Qiming Venture Partners portfolio company Attovia Therapeutics (NASDAQ: ATTO), a clinical-stage biopharmaceutical company focused on immune-mediated disease therapeutics, officially listed on the Nasdaq. The IPO priced at $17.00 per share, opened at $21.00 per share, and achieved a market cap of $904 million.
Attovia commenced operations in 2023, dedicated to developing next-generation biotherapeutics for immune-mediated diseases with high unmet clinical needs. All of the company's drug candidates are discovered through its ATTOBODY biologics platform, which is exclusively licensed worldwide from Alamar Biosciences — also a Qiming Venture Partners portfolio company. Built on an evolution-based high-throughput workflow, the platform rapidly generates highly diverse candidate molecules and supports the construction of monospecific, bispecific, and trispecific constructs.
Leveraging the ATTOBODY platform, Attovia has nominated three product candidates: ATTO-1310, ATTO-2306, and ATTO-1091. According to its prospectus, the IPO proceeds will primarily fund clinical development of ATTO-1310, ATTO-2306, and the broader pipeline including ATTO-1091.
Dr. Kan Chen, Partner and Co-Head of Healthcare at Qiming Venture Partners, commented: "Immune-mediated diseases affect enormous patient populations globally, and current treatment options still leave significant unmet clinical needs. Attovia's differentiated ATTOBODY platform, licensed from Alamar, provides a powerful toolkit for developing complex multi-specific biologics. Qiming Venture Partners has long focused on pioneering innovation in biopharmaceutical investing. We invested in Attovia from its early stages and witnessed the team advance platform technology into clinical-stage assets. We look forward to Attovia continuing to deliver innovative therapies that benefit patients worldwide."
Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq
Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq on August 5, 2026 Beijing time. Attovia Therapeutics (NASDAQ: ATTO) issued its shares at a price of $17.00 per share and opened at $21.00 per share with a market capitalization of $904 million.
Commencing operations in 2023, Attovia develops next‑generation biotherapeutics for immune‑mediated diseases with high unmet medical needs. All of Attovia's product candidates are discovered on its ATTOBODY biologics platform, which is licensed under an exclusive worldwide license from Alamar Biosciences, also a portfolio company of Qiming Venture Partners. Leveraging an evolution‑based high‑throughput workflow, the platform enables rapid discovery of highly diverse candidates that can be assembled into monospecific, bispecific and trispecific biologics.
Leveraging the ATTOBODY platform, Attovia has nominated three product candidates: ATTO‑1310, ATTO‑2306 and ATTO‑1091. As disclosed in the prospectus, proceeds from this IPO will mainly be used to advance the clinical development of ATTO‑1310, ATTO‑2306 and the research pipeline including ATTO‑1091, among other purposes.
Dr. Kan Chen, Partner and Healthcare Co-Lead at Qiming Venture Partners, commented: "Immune‑mediated diseases affect large patient populations worldwide and substantial unmet clinical needs persist with current standard‑of‑care therapies. Attovia's differentiated ATTOBODY platform, in‑licensed from Alamar Biosciences, provides a powerful engine for engineering complex multi‑specific biologics. Qiming Venture Partners maintains a long‑term focus on investing in pioneering‑innovation biotech companies. We backed Attovia at its early stage and witnessed the team advance platform technology into clinical‑stage assets. Proceeds from this Nasdaq IPO will strongly support further advancement of its core pipeline. We look forward to Attovia delivering novel therapeutics to benefit patients globally."
Past Coverage
Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol.24, 2026.8.4
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the NYSE, Nasdaq, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), Hohobio, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.